Literature DB >> 27867999

Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?

Priyanka Bhateja1, Neelesh Sharma1.   

Abstract

Entities:  

Year:  2016        PMID： 27867999      PMCID： PMC5104648          DOI： 10.21037/atm.2016.09.45

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  21 in total

1.  Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Authors:  Jean-Charles Soria; Yi-Long Wu; Kazuhiko Nakagawa; Sang-We Kim; Jin-Ji Yang; Myung-Ju Ahn; Jie Wang; James Chih-Hsin Yang; You Lu; Shinji Atagi; Santiago Ponce; Dae Ho Lee; Yunpeng Liu; Kiyotaka Yoh; Jian-Ying Zhou; Xiaojin Shi; Alan Webster; Haiyi Jiang; Tony S K Mok
Journal:  Lancet Oncol       Date:  2015-07-06       Impact factor: 41.316

2.  Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

Authors:  David R Gandara; Tianhong Li; Primo N Lara; Karen Kelly; Jonathan W Riess; Mary W Redman; Philip C Mack
Journal:  Clin Lung Cancer       Date:  2013-10-12       Impact factor: 4.785

3.  Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.

Authors:  Kenichi Nishie; Tomoya Kawaguchi; Akihiro Tamiya; Tomoyasu Mimori; Naoko Takeuchi; Yoshinobu Matsuda; Naoki Omachi; Kazuhiro Asami; Kyoichi Okishio; Shinji Atagi; Tomohisa Okuma; Akihito Kubo; Yoshihito Maruyama; Shinzoh Kudoh; Minoru Takada
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

4.  First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

Authors:  Keunchil Park; Chong-Jen Yu; Sang-We Kim; Meng-Chih Lin; Virote Sriuranpong; Chun-Ming Tsai; Jong-Seok Lee; Jin-Hyoung Kang; K C Allen Chan; Pablo Perez-Moreno; Peter Button; Myung-Ju Ahn; Tony Mok
Journal:  JAMA Oncol       Date:  2016-03       Impact factor: 31.777

5.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Authors:  Antonio Marchetti; Carla Martella; Lara Felicioni; Fabio Barassi; Simona Salvatore; Antonio Chella; Pier P Camplese; Teodorico Iarussi; Felice Mucilli; Andrea Mezzetti; Franco Cuccurullo; Rocco Sacco; Fiamma Buttitta
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

6.  Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.

Authors:  Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Authors:  Nobuyuki Katakami; Shinji Atagi; Koichi Goto; Toyoaki Hida; Takeshi Horai; Akira Inoue; Yukito Ichinose; Kunihiko Koboyashi; Koji Takeda; Katsuyuki Kiura; Kazuto Nishio; Yoko Seki; Ryuichi Ebisawa; Mehdi Shahidi; Nobuyuki Yamamoto
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

Authors:  Yelena Y Janjigian; Egbert F Smit; Harry J M Groen; Leora Horn; Scott Gettinger; D Ross Camidge; Gregory J Riely; Bushi Wang; Yali Fu; Vikram K Chand; Vincent A Miller; William Pao
Journal:  Cancer Discov       Date:  2014-07-29       Impact factor: 39.397

10.  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Authors:  M Schuler; J C-H Yang; K Park; J-H Kim; J Bennouna; Y-M Chen; C Chouaid; F De Marinis; J-F Feng; F Grossi; D-W Kim; X Liu; S Lu; J Strausz; Y Vinnyk; R Wiewrodt; C Zhou; B Wang; V K Chand; D Planchard
Journal:  Ann Oncol       Date:  2015-12-08       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.